Hospital

Mark Zangardi, PharmD, MS, BCOP, and Amber Cipriani, PharmD, BCOP, discuss the growing role of circulating tumor DNA (ctDNA) testing in oncology, highlighting its applications in early cancer detection, molecular residual disease assessment, and treatment monitoring.

Automated diagnosis verification offers a promising alternative for managing the use of GLP-1 medications.

In patients with CKD, there were negative associations between the sodium cotransporter (NCC) and its phosphorylation (pNCC) in urinary extracellular vesicles (uEVs), but further research is needed to confirm these findings in a larger cohort.

The prevalence of hepatitis D virus (HDV) antibody positivity was about 0.24% in patients with chronic hepatitis B virus (HBV).

Pharmacists play a key role in educating patients and prescribers on the selection, use, and management of GLP-1 receptor agonists in diabetes care.

Matthew Lei, PharmD, BCOP, highlights the value of community, collaboration, and innovation at the HOPA Annual Conference.

Numerical differences were observed as early as Month 1.

Sophie Jabban discusses research presented at the SGO Annual Meeting highlighting significant disparities in MRI access for patients with cervical cancer receiving chemoradiation, with delays linked to both race and insurance status, underscoring systemic barriers that may impact timely treatment.

The approval was based on efficacy and safety data from a randomized, 3-arm, open-label phase 3 CHECKMATE-8HW trial.

Advanced practice provider (APP) care models allow for health systems to better individualize care for patients, effectively meeting their needs.

Fatty acid metabolism plays a critical role in treatment responses.

Sophie Jabban discusses findings from 2 studies that highlight how geographic location, race, ethnicity, and social determinants of health contribute to delays in initiating chemoradiation for patients with cervical cancer.

The multiple myeloma landscape is evolving, with bispecific T-cell engagers offering hope.

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, offers insights for oncology pharmacists treating patients with metastatic esophageal squamous cell carcinoma.

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, discusses a case study of a patient with metastatic esophageal squamous cell carcinoma.

Tirzepatide-treated patients with chronic kidney disease (CKD), obesity, and heart failure with preserved ejection fraction (HFpEF) had improved renal function both by cystatin C and creatinine.

Beth A. Malow, MD, MS, FAAN, said that pharmacists and health care professionals are at the frontlines of collaborating and raising awareness of climate change’s impacts.

Malow also emphasized the importance of staying educated on the potential neurological risks that may occur as a result of climate change.

A significant portion of unvaccinated individuals were open to future vaccination.

The trial showed that adding pelabresib to ruxolitinib improved outcomes in myelofibrosis with manageable side effects.

The new designations span both warm autoimmune hemolytic anemia and IgG4-related disease, 2 rare, immune-mediated conditions that burden patients due to a lack of available treatment options.

BIIB080 is designed to target microtubule-associated protein tau mRNA, aimed to reduce the production of tau protein.

CAV-1 is a key protein in lipid rafts that helps control cellular processes such as growth, survival, and migration.

Pharmacists can address micronutrient deficiencies, aiding those with type 2 diabetes as they face a higher risk.

Siremadlin is a novel, investigational, second-generation antagonist that binds to MDM2.

Tocilizumab-bavi received FDA approval in September 2023 as the first biosimilar to tocilizumab for the treatment of various adult and pediatric arthritis conditions.

Generics play a crucial role in mitigating drug shortages by offering a real alternative for 80% of drugs that are becoming increasingly unavailable in Italy.

The predictive tool may reveal the mechanisms underlying treatment resistance in patients with HER+ breast cancer.

Positive results from an interim analysis of the phase 3 ALIGN study bolstered atrasentan towards receiving accelerated approval for patients with immunoglobulin A nephropathy, a rare condition that can cause kidney failure.

Real-time profiling of T-cell activation states in non-CAR T-cells may help guide treatment decisions.